Synergy (SGYP) 09/10/2016 http://www.synergypharma.com/ Pipeline: Its pipeline focuses on gastrointestinal disease and disorders including idiopathic constipation, irritable bowel syndrome and ulcerative colitis. Product Indication Status Plecanatide (SP-304) Chronic Idiopathic Constipation NDA filings Plecanatide (SP-304) Irritable bowel syndrome with constipation Phase 3 Dolcanatide (SP-333) Opioid induced constipation Phase 3 Dolcanatide (SP-333) Ulcerative colitis Phase 2
http://www.synergypharma.com/ Pipeline: Its pipeline focuses on gastrointestinal disease and disorders including idiopathic constipation, irritable bowel syndrome and ulcerative colitis. Product Indication Status Plecanatide (SP-304) Chronic Idiopathic Constipation NDA filings Plecanatide (SP-304) Irritable bowel syndrome with constipation Phase 3 Dolcanatide (SP-333) Opioid induced constipation Phase 3 Dolcanatide (SP-333) Ulcerative colitis Phase 2
